Global Lung Cancer Therapeutics Market 2016-2020

About Lung Cancer Therapeutics
Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavio’s analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA

Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
‧ F. Hofmann-La Roche
‧ Eli Lilly
‧ AstraZeneca
‧ Pfizer
‧ Celgene

Other prominent vendors
‧ Abbvie
‧ Aetna
‧ Agennix
‧ Allergan
‧ Amgen
‧ ARIAD Pharmaceuticals
‧ Astellas Pharma
‧ Betta Pharmaceuticals
‧ BeyondSpring Pharmaceuticals
‧ BioNumerik Pharmaceuticals
‧ Boehringer Ingelheim
‧ Boston Biomedical
‧ Bristol-Myers Squibb
‧ Celldex
‧ CTI BioPharma
‧ Eisai
‧ GlaxoSmithKline
‧ GTx
‧ Helsinn
‧ Hutchison Medipharma
‧ Ionis Pharmaceuticals
‧ Kadmon Corporation
‧ MabVax
‧ Merck
‧ Novartis
‧ NovaRx Corporation
‧ OncoGeneX
‧ Ono Pharmaceutical
‧ OSE Immunotherapeutics
‧ OSI Pharmaceuticals
‧ Peregrine
‧ PharmaMar
‧ Pierre Fabre
‧ Qiagen
‧ Recombio
‧ Samsung Bioepis
‧ Sanofi
‧ SFJ Pharmaceuticals
‧ Spectrum Pharmaceuticals
‧ Sumitomo Dainippon Pharma
‧ Synta
‧ Takeda Pharmaceuticals
‧ Teva Pharmaceutical
‧ Xcovery

Market driver
‧ Growing demand for targeted therapies
‧ For a full, detailed list, view our report

Market challenge
‧ Growing popularity of alternative therapeutics
‧ For a full, detailed list, view our report

Market trend
‧ Emergence of nanomedicine platform for the treatment of lung cancer
‧ For a full, detailed list, view our report

Key questions answered in this report
‧ What will the market size be in 2020 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table of Contents
PART 01: Executive summary
‧ Highlights
PART 02: Scope of the report
‧ Market overview
‧ Top-vendor offerings
PART 03: Market research methodology
‧ Research methodology
‧ Economic indicators
PART 04: Introduction
‧ Key market highlights
PART 05: Disease overview
‧ Understanding the disease
‧ Economic burden
‧ Types of lung cancer
‧ Diagnosis
‧ Staging of SCLC
‧ Staging of NSCLC
‧ Key buying criteria
PART 06: Pipeline analysis
PART 07: Market landscape
‧ Global lung cancer therapeutics market
‧ Five forces analysis
PART 08: Market segmentation by disease type
‧ NSCLC
‧ Global NSCLC market overview
‧ SCLC
‧ Global SCLC market overview
PART 09: Market segmentation by type of molecule
‧ Small molecules
‧ Biologics
PART 10: Geographical segmentation
‧ Lung cancer therapeutics market in Americas
‧ Lung cancer therapeutics market in EMEA
‧ Lung cancer therapeutics market in APAC
PART 11: Market drivers
‧ Growing demand for targeted therapies
‧ Presence of blockbuster drugs coupled with longer patent exclusivities
‧ Advancements in identification of molecular biomarkers increasing patient pool
‧ Paradigm shifts toward the adoption of checkpoint inhibitors
PART 12: Impact of drivers
PART 13: Market challenges
‧ Growing popularity of alternative therapeutics
‧ High costs leading to low adoption rate
‧ Adverse effects of drugs
PART 14: Impact of drivers and challenges
PART 15: Market trends
‧ Emergence of nanomedicine platform for the treatment of lung cancer
‧ Advent of miRNA therapeutics in the treatment of lung cancer
‧ Growing strategic alliances for late-stage pipeline
‧ Growing approvals in lung cancer therapeutics market
PART 16: Vendor landscape
‧ Competitive scenario
PART 17: Key vendor analysis
‧ F. Hoffmann-La Roche
‧ Eli Lilly
‧ AstraZeneca
‧ Pfizer
‧ Celgene
‧ Other prominent vendors
PART 18: Appendix
‧ List of abbreviations
PART 19: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global lung cancer therapeutics market
Exhibit 03: Snapshot of lung cancer
Exhibit 04: Types of lung cancer
Exhibit 05: Main diagnostic procedures to determine presence of lung cancer
Exhibit 06: Staging of SCLC
Exhibit 07: Illustration of stages of NSCLC disease
Exhibit 08: Key buying criteria for lung cancer therapeutics
Exhibit 09: Factors affecting adoption rates of lung cancer therapeutics
Exhibit 10: Pipeline analysis of key vendors in global lung cancer therapeutics market
Exhibit 11: Percentage share of drug candidates by stage of development
Exhibit 12: Phase III pipeline portfolio: Global lung cancer therapeutics market
Exhibit 13: Phase II pipeline portfolio: Global lung cancer therapeutics market
Exhibit 14: Phase I pipeline portfolio: Global lung cancer therapeutics market
Exhibit 15: Global lung cancer therapeutics market snapshot
Exhibit 16: Analysis of global lung cancer therapeutics market
Exhibit 17: Global lung cancer therapeutics market size and forecast 2015-2020 ($ billions)
Exhibit 18: Opportunity analysis of global lung cancer therapeutics market
Exhibit 19: Opportunity analysis in developed and emerging markets
Exhibit 20: Five forces analysis
Exhibit 21: Segmentation of global lung cancer therapeutics market by disease type 2015 and 2020
Exhibit 22: Life cycle analysis of key segments in global lung cancer therapeutics market 2015
Exhibit 23: Types of NSCLC
Exhibit 24: Potential drugs/drug candidates in global NSCLC therapeutics market
Exhibit 25: Key drivers impacting market growth in NSCLC
Exhibit 26: Global NSCLC therapeutics market size and forecast 2015-2020 ($ billions)
Exhibit 27: Opportunity analysis in global NSCLC market
Exhibit 28: Key points in SCLC
Exhibit 29: Key drivers impacting market growth in SCLC
Exhibit 30: Global SCLC therapeutics market size and forecast 2015-2020 ($ billions)
Exhibit 31: Opportunity analysis in global SCLC therapeutics market
Exhibit 32: Segmentation of global lung cancer therapeutics market by type of molecule 2015
Exhibit 33: Global lung cancer therapeutics market by geographical segmentation 2015-2020
Exhibit 34: Segmentation of global lung therapeutics market based on geography 2015 and 2020
Exhibit 35: Lung cancer therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 36: Lung cancer therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Key trends across various countries in Americas
Exhibit 38: Lung cancer therapeutics market size and forecast in EMEA 2015-2020 ($ billions)
Exhibit 39: Drivers in lung cancer therapeutics market in EMEA
Exhibit 40: Key strategic initiatives in various countries in EMEA
Exhibit 41: Lung cancer therapeutics market size and forecast in APAC 2015-2020 ($ billions)
Exhibit 42: Key drivers and challenges in APAC
Exhibit 43: YoY growth rate of Avastin 2015
Exhibit 44: Performance of blockbuster drugs in 2015
Exhibit 45: Patent exclusivities of few blockbuster drugs
Exhibit 46: Recent launches of checkpoint inhibitors
Exhibit 47: Impact of drivers
Exhibit 48: Alternative therapies for lung cancer therapeutics
Exhibit 49: Costs of few lung cancer drugs ($)
Exhibit 50: Force field analysis of drivers and challenges in global lung cancer therapeutics market
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Trend analysis in global lung cancer therapeutics market
Exhibit 53: Key factors driving adoption of nanomedicine
Exhibit 54: Factors driving adoption of miRNA therapeutics
Exhibit 55: Key deals in global lung cancer therapeutics market
Exhibit 56: Recent approvals of lung cancer therapeutics
Exhibit 57: Competitive analysis in global lung cancer therapeutics market
Exhibit 58: Market penetration of various lung cancer therapeutics manufacturers in global (2015)
Exhibit 59: Regional analysis of vendors in global lung cancer therapeutics market
Exhibit 60: Vendors ranking in global lung cancer therapeutics market
Exhibit 61: F. Hoffmann-La Roche: Key highlights
Exhibit 62: F. Hoffmann-La Roche: Strength assessment
Exhibit 63: F. Hoffmann-La Roche: Strategy assessment
Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 66: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
Exhibit 68: F. Hoffmann-La Roche: Geographic segmentation of Tarceva by revenue 2015
Exhibit 69: Eli Lilly: Key highlights
Exhibit 70: Eli Lilly: Strength assessment
Exhibit 71: Eli Lilly: Strategy assessment
Exhibit 72: Eli Lilly: Opportunity assessment
Exhibit 73: Eli Lilly: YoY revenue and growth rate of Alimta 2013-2015 ($ billions)
Exhibit 74: Eli Lilly: Geographic segmentation by revenue of Alimta 2015
Exhibit 75: Eli Lilly: YoY and growth rate of Cyramza 2014-2015 ($ millions)
Exhibit 76: Eli Lilly: Geographic segmentation by revenue of Cyramza 2015
Exhibit 77: AstraZeneca: Key highlights
Exhibit 78: AstraZeneca: Strength assessment
Exhibit 79: AstraZeneca: Strategy assessment
Exhibit 80: AstraZeneca: Opportunity assessment
Exhibit 81: AstraZeneca: YoY revenue and growth rate of Iressa 2013-2015 ($ billions)
Exhibit 82: AstraZeneca: Geographic segmentation of Iressa 2013-2015 (% share)
Exhibit 83: Pfizer: Key highlights
Exhibit 84: Pfizer: Strength assessment
Exhibit 85: Pfizer: Strategy assessment
Exhibit 86: Pfizer: Opportunity assessment
Exhibit 87: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
Exhibit 88: Celgene: Key highlights
Exhibit 89: Celgene: Strength assessment
Exhibit 90: Celgene: Strategy assessment
Exhibit 91: Celgene: Opportunity assessment
Exhibit 92: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)